Tomáš Eckschlager

7.4k total citations · 3 hit papers
158 papers, 5.9k citations indexed

About

Tomáš Eckschlager is a scholar working on Molecular Biology, Oncology and Nutrition and Dietetics. According to data from OpenAlex, Tomáš Eckschlager has authored 158 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Molecular Biology, 45 papers in Oncology and 37 papers in Nutrition and Dietetics. Recurrent topics in Tomáš Eckschlager's work include Trace Elements in Health (37 papers), Neuroblastoma Research and Treatments (31 papers) and Cancer therapeutics and mechanisms (27 papers). Tomáš Eckschlager is often cited by papers focused on Trace Elements in Health (37 papers), Neuroblastoma Research and Treatments (31 papers) and Cancer therapeutics and mechanisms (27 papers). Tomáš Eckschlager collaborates with scholars based in Czechia, Germany and Belgium. Tomáš Eckschlager's co-authors include Marie Stiborová, Jan Hraběta, Vojtěch Adam, René Kizek, Michal Masařík, Jaromír Gumulec, Ondřej Zítka, Jaromír Hubálek, Libuše Trnková and Soňa Křížková and has published in prestigious journals such as PLoS ONE, Cancer and Scientific Reports.

In The Last Decade

Tomáš Eckschlager

156 papers receiving 5.8k citations

Hit Papers

Histone Deacetylase Inhibitors as Anticancer Drugs 2012 2026 2016 2021 2017 2013 2012 250 500 750

Peers

Tomáš Eckschlager
Y. James Kang United States
Yang Li China
Lin Zhao China
Kelvin Cain United Kingdom
Tomáš Eckschlager
Citations per year, relative to Tomáš Eckschlager Tomáš Eckschlager (= 1×) peers Michal Masařík

Countries citing papers authored by Tomáš Eckschlager

Since Specialization
Citations

This map shows the geographic impact of Tomáš Eckschlager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Eckschlager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Eckschlager more than expected).

Fields of papers citing papers by Tomáš Eckschlager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Eckschlager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Eckschlager. The network helps show where Tomáš Eckschlager may publish in the future.

Co-authorship network of co-authors of Tomáš Eckschlager

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Eckschlager. A scholar is included among the top collaborators of Tomáš Eckschlager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Eckschlager. Tomáš Eckschlager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eckschlager, Tomáš, et al.. (2025). Lysine demethylases and cancer. Pathology - Research and Practice. 271. 156011–156011. 2 indexed citations
2.
Heger, Zbyněk, et al.. (2021). Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib. International Journal of Molecular Sciences. 22(8). 4250–4250. 5 indexed citations
3.
Indra, Radek, Petr Pompach, Václav Martínek, et al.. (2019). Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation. International Journal of Molecular Sciences. 20(14). 3392–3392. 14 indexed citations
4.
Strmiska, Vladislav, Petr Michálek, Roman Guráň, et al.. (2019). Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe‐Dnmts axis. Molecular Oncology. 13(5). 1002–1017. 13 indexed citations
5.
Kopečková, Kateřina, Tomáš Eckschlager, Jakub Širc, et al.. (2019). Nanodrugs used in cancer therapy. Biomedical Papers. 163(2). 122–131. 38 indexed citations
6.
Dostálová, Simona, Hana Polanská, Markéta Svobodová, et al.. (2018). Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin. Scientific Reports. 8(1). 8867–8867. 28 indexed citations
7.
Rodrigo, Miguel Ángel Merlos, Vivian de los Rı́os, J. Ignacio Casal, et al.. (2018). Proteomic Signature of Neuroblastoma Cells UKF-NB-4 Reveals Key Role of Lysosomal Sequestration and the Proteasome Complex in Acquiring Chemoresistance to Cisplatin. Journal of Proteome Research. 18(3). 1255–1263. 12 indexed citations
8.
Dostálová, Simona, David Hynek, Soňa Křížková, et al.. (2017). Apoferritin as an ubiquitous nanocarrier with excellent shelf life. International Journal of Nanomedicine. Volume 12. 2265–2278. 29 indexed citations
9.
Húska, Dalibor, Jaromír Hubálek, Petr Babula, et al.. (2014). Monitoring of DNA-doxorubicin interactions by electrochemical methods. Journal Of Biochemical Technology. 2(5). 18–19. 1 indexed citations
10.
Tmejová, Kateřina, Ludmila Krejčová, David Hynek, et al.. (2014). Electrochemical Study of Ellipticine Interaction with Single and Double Stranded Oligonucleotides. Anti-Cancer Agents in Medicinal Chemistry. 14(2). 331–340. 10 indexed citations
11.
Cernei, Natalia, Ondřej Zítka, Sylvie Skalíčková, et al.. (2013). Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line. Oncology Reports. 29(6). 2459–2466. 8 indexed citations
12.
Hraběta, Jan, et al.. (2012). Neuroblastoma stem cells – mechanisms of chemoresistance and histonedeacetylase inhibitors. Neoplasma. 59(6). 737–746. 20 indexed citations
13.
Křížková, Soňa, Markéta Ryvolová, Jan Hraběta, et al.. (2012). Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metabolism Reviews. 44(4). 287–301. 68 indexed citations
14.
Stiborová, Marie, Tomáš Eckschlager, Jitka Poljaková, et al.. (2012). The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment. Current Medicinal Chemistry. 19(25). 4218–4238. 58 indexed citations
15.
Gumulec, Jaromír, Michal Masařík, Soňa Křížková, et al.. (2011). Evaluation ofalpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers. Neoplasma. 59(2). 191–201. 24 indexed citations
16.
Procházka, Pavel, Antonín Libra, Zuzana Zemanová, et al.. (2011). Mechanisms of ellipticine‐mediated resistance in UKF‐NB‐4 neuroblastoma cells. Cancer Science. 103(2). 334–341. 11 indexed citations
17.
Húska, Dalibor, Vojtěch Adam, Jaromír Hubálek, et al.. (2010). Off-line coupling of automated pipetting system with square wave voltammetry as a tool for study of drug-DNA interaction. 28(5). 18–20. 5 indexed citations
18.
Ludvı́ková, Viera, et al.. (2010). In vitro and in vivo effects of reovirus on HPV16-transformed mice cells. Neoplasma. 57(3). 207–214. 1 indexed citations
19.
Vícha, Aleš, et al.. (2005). Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.. PubMed. 52(5). 415–9. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026